Cinclus Pharma Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 12

Employees

  • Stock Symbol
  • CINPHA

Stock Symbol

  • Share Price
  • $1.57
  • (As of Friday Closing)

Cinclus Pharma General Information

Description

Cinclus Pharma Holding AB is a clinical stage pharmaceutical company developing a drug for the treatment of erosive gastroesophageal reflux diseases, and a dual therapy treatment with an antibiotic targeting Helicobacter pylori which is a bacteria that occurs in the gastric and duodenal mucosa. The Company's main target population is patients suffering from severe eGERD, where there is a lack of satisfactory treatment options.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Kungsbron 1 Level 3
  • Elevator G
  • 111 22 Stockholm
  • Sweden
+46 08-13
Primary Industry
Drug Discovery
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Kungsbron 1 Level 3
  • Elevator G
  • 111 22 Stockholm
  • Sweden
+46 08-13

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cinclus Pharma Stock Performance

As of 14-Feb-2025, Cinclus Pharma’s stock price is $1.57. Its current market cap is $73.2M with 46.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.57 $1.56 $1.54 - $3.83 $73.2M 46.5M 83.3K -$0.42

Cinclus Pharma Financials Summary

As of 30-Sep-2024, Cinclus Pharma has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 64,968
Revenue 0 561 1,042 0
EBITDA (15,207) (19,658) (22,770) (8,870)
Net Income (14,972) (20,239) (24,552) (8,881)
Total Assets 65,194 9,447 17,808 16,263
Total Debt 44 13,044 52 161
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cinclus Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cinclus Pharma‘s full profile, request access.

Request a free trial

Cinclus Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Cinclus Pharma‘s full profile, request access.

Request a free trial

Cinclus Pharma Patents

Cinclus Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230257378-A1 Polymorphs of the hydrochloride salt of linaprazan glurate Active 05-Nov-2021
US-11820772-B2 Polymorphs of the hydrochloride salt of linaprazan glurate Active 05-Nov-2021
US-20240067644-A1 Polymorphs of the hydrochloride salt of linaprazan glurate Pending 05-Nov-2021
US-20220002297-A1 Polymorphs of x842 Inactive 02-Jul-2020
AU-2020377451-A1 Oral formulation of x842 Pending 04-Nov-2019 A61K31/437
To view Cinclus Pharma’s complete patent history, request access »

Cinclus Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cinclus Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cinclus Pharma‘s full profile, request access.

Request a free trial

Cinclus Pharma ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Cinclus Pharma’s complete esg history, request access »

Cinclus Pharma FAQs

  • When was Cinclus Pharma founded?

    Cinclus Pharma was founded in 2014.

  • Where is Cinclus Pharma headquartered?

    Cinclus Pharma is headquartered in Stockholm, Sweden.

  • What is the size of Cinclus Pharma?

    Cinclus Pharma has 12 total employees.

  • What industry is Cinclus Pharma in?

    Cinclus Pharma’s primary industry is Drug Discovery.

  • Is Cinclus Pharma a private or public company?

    Cinclus Pharma is a Public company.

  • What is Cinclus Pharma’s stock symbol?

    The ticker symbol for Cinclus Pharma is CINPHA.

  • What is the current stock price of Cinclus Pharma?

    As of 14-Feb-2025 the stock price of Cinclus Pharma is $1.57.

  • What is the current market cap of Cinclus Pharma?

    The current market capitalization of Cinclus Pharma is $73.2M.

  • What is Cinclus Pharma’s annual earnings per share (EPS)?

    Cinclus Pharma’s EPS for 12 months was -$0.42.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »